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Graphical abstract
PSC patients were divided into groups characterized by high and low age acceleration based
on the median age acceleration value (11.1 years) in the total cohort.
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Highlights Lay summary
 A peripheral blood DNA methylation (DNAm) score
identifies age acceleration in PSC patients vs.
healthy controls.
 PSC patients with high age acceleration had
significantly more PSC-related events than those
with low age acceleration.
 These findings may enable stratification of at-risk
PSC patients based on a DNAm score from periph-
eral blood.https://doi.org/10.1016/j.jhepr.2019.11.004An epigenetic clock based on DNA methylation has
been proposed as a marker of age. In liver diseases
such as non-alcoholic steatohepatitis, age acceleration
based on this epigenetic clock has been observed.
Herein, we show that patients with primary sclerosing
cholangitis have marked age acceleration, which is
further accentuated by worsening fibrosis. This mea-
sure of age acceleration could be a useful marker for
prognostication or risk stratification in primary scle-
rosing cholangitis.
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Background & Aims: A DNA methylation (DNAm) signature derived from 353 CpG sites (the Horvath clock) has been
proposed as an epigenetic measure of chronological and biological age. This epigenetic signature is accelerated in diverse
tissue types in various disorders, including non-alcoholic steatohepatitis, and is associated with mortality. Here, we assayed
whole blood DNAm to explore age acceleration in patients with primary sclerosing cholangitis (PSC).
Methods: Using the MethylationEPIC BeadChip (850K) array, DNAm signatures in whole blood were analyzed in 36 patients
with PSC enrolled in a 96-week trial of simtuzumab (Ishak F0-1, n = 13; F5-6, n = 23). Age acceleration was calculated as the
difference between DNAm age and chronological age. Comparisons between patients with high and low age acceleration
(>− vs. < the median) were made and Cox regression evaluated the association between age acceleration and PSC-related
clinical events (e.g. decompensation, cholangitis, transplantation).
Results: Age acceleration was significantly higher in patients with PSC compared to a healthy reference cohort (median, 11.1
years, p <2.2 × 10-16). In PSC, demographics, presence of inflammatory bowel disease, and ursodeoxycholic acid use were
similar between patients with low and high age acceleration. However, patients with high age acceleration had increased
serum alkaline phosphatase, gamma glutamyltransferase, alanine aminotransferase, enhanced liver fibrosis test scores, and
greater hepatic collagen and a-smooth muscle actin expression on liver biopsy (all p <0.05). Moreover, patients with high age
acceleration had an increased prevalence of cirrhosis (89% vs. 39%; p = 0.006) and greater likelihood of PSC-related events
(hazard ratio 4.19; 95% CI 1.15–15.24).
Conclusion: This analysis of blood DNAm profiles suggests that compared with healthy controls, patients with PSC –
particularly those with cirrhosis - exhibit significant acceleration of epigenetic age. Future studies are required to evaluate
the prognostic implications and effect of therapies on global methylation patterns and age acceleration in PSC.
© 2019 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Primary sclerosing cholangitis (PSC) is a complex cholestatic
liver disease characterized by inflammation and scarring of the
intra and/or extrahepatic bile ducts, with a markedly elevated
risk of developing several malignancies, most notably chol-
angiocarcinoma. The pathogenesis of PSC remains poorly un-
derstood and currently no pharmacological therapy is available.1
The histological appearance is marked by a chronic inflamma-
tory infiltrate and fibro-obliterative destruction of the bile ducts.Keywords: Aging; biomarker; inflammatory bowel disease; primary sclerosing
cholangitis; prognosis; ursodeoxycholic acid.
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E-mail address: michael.trauner@meduniwien.ac.at (M. Trauner).Assessment of liver injury by biopsy is a standard method of
assessing chronic injury, but the regional heterogeneity character-
istic of PSC accentuates sampling variability;moreover, liver biopsy
is restricted to evaluation of smaller intrahepatic bile ducts.
Although liver biopsy is not currently recommended by practice
guidelines,2 histological staging likelyhasprognostic valueandmay
represent a key endpoint in clinical trials.3,4 Beyond liver biopsy,
novel surrogate markers of fibrosis (e.g. the enhanced liver fibrosis
[ELFTM] test) that provide a global assessment may also provide
meaningful prognostic information.5
Epigenetic-based estimates of biological age using a DNA
methylation (DNAm) signature (i.e. DNAm age) assayed from
whole blood or tissue are a promising new technique to ascer-
tain a biological ‘snapshot’ of aging. One such ‘epigenetic clock’
accurately predicts an individual’s age based on methylation
levels at 353 CpG sites. This epigenetic clock has been validated
Research articlein multiple cohorts and has demonstrated predictive utility
across different tissue sites including the liver.6–8 Cases where a
person’s epigenetic age exceeds their chronological age repre-
sent a state of age acceleration with consequences for devel-
oping overt manifestations of disease.7,8
Determination of age acceleration may have practical con-
sequences. For instance, successful liver transplantation from
chronologically old, but biologically ‘fit’ donors reflects the clear
distinction between biological vs. chronological age.9 The
converse is also true as the intrinsic rate of the DNAm clock can
be altered by diseases that involve the liver. HIV and obesity
predispose to increased liver injury, and both accelerate the
epigenetic clock more than would be expected from age-
matched control specimens.8,10,11 Our group previously re-
ported that patients with non-alcoholic steatohepatitis (NASH)
and moderate to severe fibrosis demonstrate age acceleration
compared to their healthy counterparts based on a DNAm
signature from whole blood.12 In this setting, age acceleration
was associated with hepatic fibrosis, the only independent
predictor of adverse liver-related outcomes in NASH.13,14 In
other conditions, age acceleration has been associated with
poorer performance on a range of physical and cognitive as-
sessments, and higher overall mortality even after adjusting for
known risk factors.15,16
Whether age acceleration is a reflection of the fibrogenic
process across different liver diseases is unknown. If this
were indeed the case, then age acceleration in patients with
NASH would be comparable to that of patients with PSC with
similar fibrosis severity. In the current study, we confirmed
the hypothesis that patients with PSC have higher age ac-
celeration than a control population. Moreover, in patients
with PSC, age acceleration reflects the severity of hepatic
fibrosis and is associated with an increased risk of liver-
related complications. These findings support the use of a
novel, non-invasive method (based on a peripheral blood
DNAm signature) to assess the biological fitness of patients
with PSC and stratify them according to their risk of clinical
events.Materials and methods
Study population
The PSC study population was derived from a phase IIb, placebo-
controlled trial of simtuzumab, a LOXL2 inhibitor, as described
elsewhere.17 Since simtuzumab demonstrated no evidence of
efficacy in this trial for clinical or histologic endpoints, both
placebo- and simtuzumab-treated patients were included in the
current analysis. Centrally read liver biopsies were obtained at
baseline and fibrosis was staged according to the Ishak classi-
fication. For the purpose of this analysis, the study population
was restricted to patients with no-to-mild fibrosis (Ishak F0-1)
or cirrhosis (F5-6).
The healthy reference samples were chosen from a pub-
licly available DNAm database18 such that the age and sex
distribution of the chosen 50 samples matched the PSC
dataset. Specifically, each reference sample was assigned a
weight based on the age and sex distribution of the PSC
cohort, such that the reference samples with greater weights
were more like the PSC cohort than samples with lower
weights. Fifty reference samples were then chosen at random
using a method that was biased toward choosing samples
with greater weight.JHEP Reports 2020Sample collection and methylation analysis
DNA extracted from PBMCs was assayed for cytosine methyl-
ation using the Infinium Methylation Assay (850k platform), as
described by the manufacturer. DNA was treated with sodium
bisulfite to convert unmethylated cytosines to uracil, leaving
methylated cytosines unchanged. The treated DNA sample was
then denatured, neutralized, and isothermally amplified. The
amplified DNA was fragmented, precipitated with isopropanol
and re-suspended prior to hybridization onto BeadChips. The
converted and non-converted amplified DNAs were hybridized
to their corresponding probes, and excess DNA was washed
away. Hybridized DNAs then underwent single-base extension
and staining for labeling, followed by scanning on an Illumina
iScan instrument for detection. Scanned images were then
analyzed using Illumina Genome Studio (version 2.0) software.
DNAm data were processed using the minfi R Bioconductor
package version 1.2,19 and wateRmelon package version 1.18.20
DNAm data were quantile normalized.
Epigenetic age and determination of differential DNAm
Epigenetic age, based on the Horvathmodel, was calculated from
the methylation beta values using the minfi’s agep function. Age
acceleration was calculated as the difference between an in-
dividual’s DNAm age and chronological age. Differential DNAm
analysis, using methylation M values, was restricted to include
DNAm probes that do not overlap known single nucleotide
polymorphisms (SNPs) and are not thought to be cross-reactive,
as described previously.21,22 This analysis was implemented in
rmSNPandCH function (part of the DMRcate package23), which
resulted in removal of 51,695 probes. Tests for differential
methylation were carried out using the limma R package
version 3.3.24 A false discovery rate (FDR)-adjusted p value of
0.1 was used to identify differentially methylated probes. Probe
to gene mapping was achieved using a processed version of an
array manufacturer’s microarray annotation file.25
Ingenuity Pathway Analysis
Genomic DNAm and the relationship between different
methylation of genes was analyzed using Ingenuity® Pathway
Analysis (IPA) software (Ingenuity Systems, Redwood City, CA).
Networks of methylated genes were algorithmically generated
based on their connectivity and assigned a score. Scores were
used to rank signaling and developmental pathway networks
according to their methylation content.
Statistical analyses
The PSC cohort was categorized as having low or high age ac-
celeration based on the median age acceleration value in the
cohort (<11.1 years vs. >−11.1 years). Comparisons between groups
were made using Wilcoxon rank-sum tests. In addition, time to
first PSC-related clinical event (defined as ascending cholangitis,
hepatic decompensation [e.g. ascites, variceal hemorrhage, he-
patic encephalopathy], cholangiocarcinoma, hepatocellular car-
cinoma, liver transplantation, and death) was assessed using
Kaplan-Meier and Cox proportional hazards regression anal-
ysis using the survival R package version 2.41.26
Study approval
The study was approved by the Institutional Review Boards of
contributing institutions to this study. Written informed con-
sent was obtained from each individual prior to his or her
participation in the study.2vol. 2 j 100060
Table 1. Demographic and baseline characteristics of patients with PSC.
Total (n = 36) Low age acceleration (n = 18) High age acceleration (n = 18) p value
Demographics
Age, years 47 (38–51) 49 (42–54) 43.5 (35–48) 0.10
European descent 30 (83.3) 15 (83.3) 15 (83.3) 0.57
African American 4 (11.1) 2 (11.1) 2 (11.1)
Native American or Alaska native 1 (2.8) 1 (5.6) 0 (0)
Other race 1 (2.8) 0 (0) 1 (5.6)
Female 8 (22.2) 4 (22) 4 (22) 1.0
BMI, kg/m2 24.8 (23–30) 24.8 (23–28) 26.3 (23–31) 0.70
IBD 17 (47.2) 9 (50) 8 (44.4) 1.0
UDCA use 24 (66.7) 12 (66.7) 12 (66.7) 1.0
Liver biochemistry
ALT, U/L 52.5 (27–107) 29 (21–52) 83 (56–110) 0.013
ALP, U/L 250 (119–459) 125.5 (92–196) 365.5 (261–599) 0.0008
GGT, U/L 171.5 (69–459) 84.5 (50–162) 373 (178–521) 0.006
Liver histology
F0-1 fibrosis 13 (36.1) 11 (61.1) 2 (11.1) 0.006
F5-6 fibrosis 23 (63.9) 7 (38.9) 16 (88.9)
Hepatic collagen, % 4.5 (2–9) 2.7 (2–6) 8.2 (4–14) 0.005
a-SMA expression, % 4.6 (1–12) 1.3 (1–5) 11.4 (4–14) 0.003
Serum markers
ELF 9.9 (9–11) 9.23 (8–11) 10.9 (10–12) 0.024
IL-8, pg/ml 29.5 (14–69) 15.5 (11–30) 53 (29–134) 0.0007
Total bile acids, ng/ml 5,409 (2,249–9,973) 4,390 (1,494–5,409) 9,207 (6,575–43,978) 0.11
Comparisons between groups were made using Wilcoxon rank-sum tests. The chi-squared test was used to compare categorical frequencies.
ALP, alkaline phosphatase; ALT, alanine aminotransferase; IL-8, interleukin-8; GGT, gamma-glutamyltransferase; PSC, PSC, primary sclerosing cholangitis; SMA, smooth
muscle actin; UDCA, ursodeoxycholic acid.
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Fig. 1. Relationship between DNAm and chronological age. DNAm age
(y-axis) is presented as a function of chronological age (x-axis) for individuals
with PSC. The regression line is presented as a dashed line. The identity line is
presented as a solid line. Vertical distance between each point and the
identity line is representative of age acceleration. Patients with high age ac-
celeration (circles) have age acceleration at or above the median value,
whereas patients with low age acceleration (triangles) have age acceleration
below the median value. The scatterplot is annotated with the Pearson cor-
relation coefficient and its p value between DNAm and chronological age.
DNAm, DNA methylation; PSC, primary sclerosing cholangitis.Results
The study population included 36 patients with PSC enrolled
in a 96-week, phase IIb study of simtuzumab, a monoclonal
antibody directed against lysyl oxidase-like-2 (LOXL2).17 The
median age of the PSC cohort was 47 years; median body mass
index (BMI) was 25 kg/m2, and the majority (78%) were male.
Additional demographic and clinical characteristics of the PSC
cohort are included in Table 1. In this cohort, the DNAm age
and chronological age were highly correlated (r = 0.93; p = 3.6
× 10-16; Fig. 1). Importantly, in every patient with PSC, the
DNAm age was greater than the chronological age, with a
median difference between DNAm and chronological age (age
acceleration) of 11.1 years (range 3.4–21.6). In contrast to
patients with PSC, the median age acceleration of an age/sex-
matched healthy cohort18 (Table S1) was not significantly
different from 0 (median age acceleration = 0.3 years; p = 0.9)
(Fig. S1).
Association between age acceleration and hepatic fibrosis in
PSC
Next, we determined whether age acceleration is associated
with the severity of liver fibrosis in patients with PSC. Specif-
ically, we evaluated whether patients with PSC and no-to-mild
fibrosis (Ishak stages F0-1 [n=13]) have less age acceleration
compared to those with cirrhosis (Ishak stages F5-6 [n=23]). Our
results indicate that patients with PSC and cirrhosis exhibit
significantly more age acceleration than those with F0-1 fibrosis
(median age acceleration, 12.1 vs. 9.5 years; p = 0.002) (Fig. 2).
We also categorized patients with PSC into 2 groups, those at or
above vs. below the median value of age acceleration (11.1 years)
(Table 1). Compared with patients with low age acceleration,
those with high age acceleration had greater hepatic collagen
content (2.7% vs. 8.2%; p = 0.005) and a-smooth muscle actin (a-
SMA) expression (1.3% vs. 11.4%; p = 0.003) on liver biopsy, and
higher ELF scores (9.2 vs. 10.9; p = 0.024). As previously noted inJHEP Reports 2020patients with NASH-related liver fibrosis, these data support an
association between hepatic fibrosis and age acceleration in
patients with PSC.3vol. 2 j 100060
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Fig. 2. Age acceleration in patients with PSC. Age acceleration, the differ-
ence between DNAm and chronological age, plotted for patients with PSC
based on Ishak fibrosis stage at baseline. Age acceleration is significantly
greater in patients with Ishak F5-6 fibrosis vs. F0-1 fibrosis (p = 0.002). DNAm,
DNA methylation; PSC, primary sclerosing cholangitis.
Research articleAssociations between age acceleration and other baseline
characteristics
No significant differences in sex, race, BMI, or use of urso-
deoxycholic acid (UDCA) were observed between patients with
PSC and low vs. high age acceleration (Table 1). Consistent with
previous findings,27 the presence of inflammatory bowel disease
(IBD) was not associated with age acceleration. However, me-
dian age was non-significantly lower in patients with high age
acceleration (44 vs. 49 years, p = 0.10). Moreover, compared with
patients with low age acceleration, those with high age accel-
eration had greater median serum alkaline phosphatase (ALP)
(125.5 vs. 365.5 U/L; p <0.001), gamma-glutamyltransferase
(GGT) (84.5 vs. 373 U/L; p = 0.006), and alanine aminotrans-
ferase (29 vs. 83 U/L; p = 0.013). In addition, serum levels of
interleukin (IL)-8, which have been associated with disease
progression, were higher in patients with high vs. low age ac-
celeration (53 vs. 15.5 pg/ml; p = 0.0007).Association between age acceleration and PSC-related
clinical events
We next asked whether patients with PSC and high age ac-
celeration had a greater risk of PSC-related clinical events (i.e.
ascending cholangitis, hepatic decompensation, liver trans-
plantation, cholangiocarcinoma) compared to the low age ac-
celeration group. During a median follow-up of 23 months
(range 1–26), 13 individuals (36%) developed PSC-relatedTable 2. PSC-related clinical events according to age acceleration.
Low age
acceleration
(n = 18)
High age
acceleration
(n = 18)
All PSC progression events 3 10
Ascites 0 1
Bilirubin elevated 0 1
Ascending cholangitis 3 3
Hepatic encephalopathy 0 2
Esophageal varices 0 3
PSC, primary sclerosing cholangitis.
JHEP Reports 2020clinical events. In total, 10/18 (56%) patients with high age
acceleration vs. 3/18 (17%) with low age acceleration had an
event (Table 2). In Kaplan-Meier analysis, survival free of PSC-
related clinical events was reduced in patients with PSC and
high age acceleration (log-rank p = 0.018) (Fig. 3A). Compared
to patients with low age acceleration, those with high age
acceleration had an approximately 4-fold higher risk of PSC-
related events (hazard ratio 4.19; 95% CI 1.15–15.24; p =
0.03). In patients with cirrhosis (F5-6) specifically, the pres-
ence of high age acceleration also conferred a greater likeli-
hood of clinical disease progression (Fig. 3B). These results
suggest that a greater difference between DNAm-based age
and chronological age is associated with an increased risk of
disease progression in PSC.
Differential methylation patterns according to fibrosis stage
To assess whether global DNAm patterns exist that distinguish
patients with PSC and no-to-mild (F0-1) fibrosis from those
with cirrhosis (F5-6), we performed differential DNAm analysis
on the PSC cohort. After correcting for multiple testing (FDR
cut-off of 0.1), we identified 19 differentially methylated
probes between the low and high fibrosis groups that map to
20 genes (Fig. 4). A pathway enrichment analysis identified
collagen formation as the top enriched pathway (FDR q-value =
0.003) based on the presence of 3 genes in the differentially
methylated list: COL4A1 (collagen, type IV, alpha 1), COL4A2
(collagen, type IV, alpha 2), and CRTAP (cartilage associated
protein).Discussion
The current study identified age acceleration in patients with
PSC enrolled in a controlled clinical trial. In contrast to other
chronic diseases such as NASH or HIV infection, where age
acceleration has been determined to be in the range of 5 to 7
years, far greater age acceleration was observed in the cur-
rent PSC cohort.10,12,28 Specifically, PSC patients with mini-
mal fibrosis or cirrhosis demonstrated median age
acceleration of approximately 10 and 12 years, respectively,
greater than a control population. These divergent levels of
age acceleration, despite the presence of advanced fibrosis in
both the NASH and PSC cohorts, suggest distinct epigenetic
evidence of aging in these 2 liver diseases. Moreover, greater
fibrosis on liver biopsy and higher serum markers of chole-
stasis were associated with additional age acceleration,
thereby allowing for potential risk stratification from a pe-
ripheral blood sample.
The distinction between chronological and biological age is a
useful one in chronic conditions such as PSC where the latency
period between the initial diagnosis and clinical manifestations
can be decades. Determination of the epigenetic clock and its
deviation from chronological age could help gauge the unique
impact of a disease on a particular individual. From a practical
standpoint, the current study found that despite being 6 years
younger chronologically than the low age acceleration group,
the group with high age acceleration had more fibrosis, more
severe cholestasis, and an approximately 4-fold increased risk of
PSC-related clinical events. Notably, all portal hypertension-
related clinical events were in the high age acceleration group,
whereas only episodes of ascending cholangitis were observed
in the low age acceleration group. Despite the small sample set
of this study, the use of biological age assessed by this4vol. 2 j 100060
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Research articleperipheral blood DNAm signature rather than chronological age
may provide a novel method to risk stratify patients with this
disease.
The cause(s) of the marked age acceleration observed in this
PSC cohort is unclear; however, obesity, the use of UDCA, and
concomitant IBD do not appear to play a role. The absence of an
association between age acceleration and UDCA use is consistent
with the lack of clear clinical benefit of UDCA in PSC. While the
lack of association with concomitant IBD could be explained by
the relatively quiescent intestinal disease in this cohort, addi-
tional study is warranted based on the prognostic impact of
IBD on the progression of PSC.29,30 One potential explanation
for our findings may be the presence of cellular senescence
that has been reported in cholangiopathies including PSC. Sasaki
et al. described the presence of markers of cholangiocyte senes-
cence in PSC livers and found increased senescent cholangiocytes
compared to controls.31 Subsequent studies confirmed the
presence of senescence markers in PSC in the setting of intact
telomere sequences, consistent with a non-replicative, stress-
induced senescent phenotype.32,33 This secretory phenotype is
marked by the significant expression and production of pro-
inflammatory cytokines IL-6 and IL-8.32 The latter cytokine has
particular relevance in PSC, as higher serum levels of IL-8 have
been associated with an increased risk of clinical events.34 In
the current study, compared to patients with PSC and low
age acceleration, those with high age acceleration had greater
serum levels of IL-8 and an increased risk of PSC-related com-
plications. Thus, a link between cholangiocyte senescence, an
inflammation-associated secretory phenotype, and elevated IL-8
levels associated with clinical decompensation are consistent
with an overall global picture of organ dysfunction in PSC.34,35
Our data showing significant associations between age
acceleration with serum ALP and GGT, as well as a trend toJHEP Reports 2020increased serum bile acids in patients with high age ac-
celeration, suggest a link between the severity of chole-
stasis and accelerated aging in PSC. Indeed, prior studies
have observed direct effects of bile acids on DNA methyl-
ation.36,37 The composition of specific bile acid species may
also contribute to the inflammation-related senescent
phenotype. A previous study found that bile acids such as
deoxycholic acid contribute to the senescent and inflam-
matory characteristics of hepatic stellate cells, which
combined with high fat feeding leads to fibrosis and hep-
atocarcinogenesis.38 Identification of specific bile acid spe-
cies as a driver of liver disease is consistent with previous
work that noted the development of liver cancer with
deletion of the farnesoid X receptor, the major transcrip-
tional regulator of bile acid homeostasis.39,40 Whether al-
terations in bile acids alone contribute to age acceleration
or merely represent one notable feature of organ dysfunc-
tion brought on by age acceleration is unclear. However,
the current experimental data suggests that the biologic
clock represents an epigenetic maintenance system that
may be distinct from the process of senescence.41 It would
therefore be important to determine whether age acceler-
ation in PSC occurs in the earliest stages of PSC, prior to
the onset of the senescent phenotype and its associated
inflammatory phenotype.
In conclusion, we have identified marked age acceleration in
a PSC cohort with varying stages of fibrosis compared with a
healthy control population based on a peripheral blood DNAm
signature. In patients with PSC, age acceleration is associated
with increased hepatic fibrosis, biochemical markers of chole-
stasis, and a higher risk of PSC-related clinical events. These
findings provide a potentially novel and useful approach to risk
stratification in PSC.Abbreviations
ALP, alkaline phosphatase; ALT, alanine aminotransferase; BMI, body
mass index; DNAm, DNA methylation; ELF, enhanced liver fibrosis; FDR,
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